Literature DB >> 32711713

The hope and hype of telepsychiatry during the COVID-19 pandemic.

Tanjir Rashid Soron1, Sheikh Mohammed Shariful Islam2, Helal Uddin Ahmed3, Syed Ishtiaque Ahmed4.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32711713      PMCID: PMC7377699          DOI: 10.1016/S2215-0366(20)30260-1

Source DB:  PubMed          Journal:  Lancet Psychiatry        ISSN: 2215-0366            Impact factor:   27.083


× No keyword cloud information.
During the COVID-19 pandemic, telepsychiatry services have received increased attention and had unprecedented growth worldwide. Governments have encouraged academic institutions, professional associations, entrepreneurs, and companies to provide telemedical and telepsychiatry services and relaxed existing rules and regulations. Mental health professionals and companies are using Zoom, Skype, WhatsApp, Facebook, and other popular freely available platforms to provide online psychiatric services rather than developing a secured and dedicated hotline or mobile phone app with the help of digital health experts and IT professionals. Even non-professional personnel can provide so-called telepsychiatry services as there are no regulatory bodies in many low-income and middle-income countries, such as in Bangladesh. Though this type of basic telepsychiatry service is gaining popularity among mental health professionals and clients in Bangladesh, we should not underestimate the risk and long-term negative consequences of these unplanned, sporadic, and unsupervised services. Health professionals put their privacy and personal life at risk by sharing their phone numbers and social media profiles publicly for telepsychiatry services. By sharing their personal information health professionals could be exposed to overwhelming numbers of intrusive and unproductive calls and messages. Telepsychiatry could be most helpful for people who are poor, refugees, or living in remote and rural areas in Bangladesh. However, their access to telepsychiatry services might be limited by their inability to purchase a suitable device. Their access could be further restricted by having poor or no mobile network or internet coverage, being exposed to social stigma, and living in a financial crisis. The financial dynamics are becoming more complicated because economic collapse is forcing the vulnerable community to prioritise food over mental health care. There are insufficient data on the acceptability, reliability, and interoperability of digital health services, or the incentives of patients and professionals to use them. The hype of telepsychiatry might create an extra burden to existing health-care systems as they will need to monitor and control telepsychiatry services. The accelerated investment of government and other stakeholders in telepsychiatry services might deprive other vital sectors in the health-care systems of funding. Telehealth is a disruptive process and without appropriate supervision and monitoring, it can lead to negative consequences. The tendency to provide false and misleading information during teleconsultation is another threat to this emerging health sector in Bangladesh. Professionals should consider the different cognitive skills and knowledge of their clients to ensure their information is clearly and completely received. As telepsychiatry services gain popularity, the relevant policy makers and device manufacturers or service providers should recognise the digital divide and consider the ethical challenges of ensuring equitable access and privacy protection. Both the clients and professionals need training and practice to optimise the benefits of the service. Telepsychiatry services should be culture and context specific, keeping the clients at the centre of care. Governments and regulatory authorities should develop and enforce strategies and recommendations for appropriate, risk-based regulatory frameworks on telepsychiatry. Telepsychiatry can serve millions of people who have or are at risk of developing a mental illness during the COVID-19 pandemic and afterwards; however, the services need to be evidence based, organised, and sustainable.
  7 in total

Review 1.  Evidence Synthesis of Digital Interventions to Mitigate the Negative Impact of the COVID-19 Pandemic on Public Mental Health: Rapid Meta-review.

Authors:  Christian Rauschenberg; Anita Schick; Dusan Hirjak; Andreas Seidler; Isabell Paetzold; Christian Apfelbacher; Steffi G Riedel-Heller; Ulrich Reininghaus
Journal:  J Med Internet Res       Date:  2021-03-10       Impact factor: 5.428

Review 2.  Prevalence of anxiety and depression in South Asia during COVID-19: A systematic review and meta-analysis.

Authors:  Md Mahbub Hossain; Mariya Rahman; Nusrat Fahmida Trisha; Samia Tasnim; Tasmiah Nuzhath; Nishat Tasnim Hasan; Heather Clark; Arindam Das; E Lisako J McKyer; Helal Uddin Ahmed; Ping Ma
Journal:  Heliyon       Date:  2021-04-05

Review 3.  The Application of e-Mental Health in Response to COVID-19: Scoping Review and Bibliometric Analysis.

Authors:  Louise A Ellis; Isabelle Meulenbroeks; Kate Churruca; Chiara Pomare; Sarah Hatem; Reema Harrison; Yvonne Zurynski; Jeffrey Braithwaite
Journal:  JMIR Ment Health       Date:  2021-12-06

4.  Changes in cannabis use and associated correlates during France's first COVID-19 lockdown in daily cannabis users: results from a large community-based online survey.

Authors:  Salim Mezaache; Cécile Donadille; Victor Martin; Maëla Le Brun Gadelius; Laurent Appel; Bruno Spire; Laelia Briand Madrid; Martin Bastien; Perrine Roux
Journal:  Harm Reduct J       Date:  2022-03-15

5.  A Survey of Mobile Apps for the Care Management of Patients with Dementia.

Authors:  Hsiao-Lun Kuo; Chun-Hung Chang; Wei-Fen Ma
Journal:  Healthcare (Basel)       Date:  2022-06-23

6.  The Reorganization of a Psychiatric Unit During COVID-19: A Reflection for Psychiatric Hospital Design.

Authors:  Jodi Sturge; Ferdi Starrenburg
Journal:  HERD       Date:  2022-05-12

7.  Virtual Twelve Step Meeting Attendance During the COVID-19 Period: A Study of Members of Narcotics Anonymous.

Authors:  Marc Galanter; William L White; Brooke Hunter
Journal:  J Addict Med       Date:  2022 Mar-Apr 01       Impact factor: 3.702

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.